Roadmap for 2026

Dear Viska Investors and Supporters,

2025 was a pivotal year for Viska Bio. We demonstrated that VISK-103 extended survival and slowed tumor growth in mouse models of both glioblastoma and colorectal cancer. Critically, combining VISK-103 with a PD-1 checkpoint inhibitor enhanced the inhibitor's efficacy, validating our therapeutic approach. These results position us well for additional in vivo efficacy studies planned for early 2026.

Our path to an IND filing is now clearly defined. We are poised to nominate a drug candidate for GLP toxicology and GMP manufacturing, supporting both our IND submission and subsequent clinical studies. A key milestone in the first half of 2026 will be demonstrating that our approach can induce immune-mediated tumor regression in vivo.

We are also bringing our vision of a platform technology to life. Our second fusion protein, VISK-200 for multiple myeloma, will soon undergo in vitro efficacy testing. VISK-300, targeting triple-negative breast cancer, has been designed and is scheduled for production and testing later this year.

The biotech community has taken notice. In 2025, we won the Golden Ticket Award from Servier, the Luminescence Prize at BIO Boston, and presented at the BIO Startup Showcase and New England Venture Forum. This February, we'll present at the Glioblastoma Summit and IO360 in Boston.

2026 holds tremendous promise for advancing our science and translating it into meaningful patient benefits. While a cure may seem ambitious, we are working every day to bring that possibility closer to reality.

Check out the rest of our newsletter here.

Warm regards,

Eric